Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection

Leukemia volume 19, pages 1265–1267 (2005)Cite this article

TO THE EDITOR

Imatinib mesylate (IM) has now become the first-line standard therapy for patients with newly diagnosed CML.1 Recent data showed, however, that resistance to IM can develop in patients in more aggressive phases of their disease, due to a variety of mechanisms including ABL kinase domain mutations that interfere with IM binding.2, 3, 4 Although the mechanisms of the occurrence of such mutations remain poorly understood, it has been shown that they can occur prior to the introduction of IM, suggesting the possibility of a clonal selection under IM therapy in some patients.5 It is however possible that mutations could also occur during IM therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  Google Scholar 

  2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  Google Scholar 

  3. Hochhaus A . Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40: 69–79.

    Article  CAS  Google Scholar 

  4. Hochhaus A, La Rosee P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331.

    Article  CAS  Google Scholar 

  5. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018.

    Article  CAS  Google Scholar 

  6. Dugray A, Geay JF, Foudi A, Bonnet ML, Vainchenker W, Wendling F et al. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia 2001; 15: 1658–1662.

    Article  CAS  Google Scholar 

  7. Miething C, Grundler R, Hoepfl J, Mugler C, Gschaidmeier H, Peschel C et al. Mice with a CML-like disease relapse with ALL under STI571 treatment. Exp Hematol 2002; 30: 96a.

    Google Scholar 

  8. Wolff NC, Ilaria Jr RL . Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 2001; 98: 2808–2816.

    Article  CAS  Google Scholar 

  9. Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831–843.

    Article  CAS  Google Scholar 

  10. Von Bubnoff N, Veach DR, Van Der KH, Aulitzky WE, Sanger J, Seipel P et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105: 1652–1659.

    Article  CAS  Google Scholar 

  11. Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia 2005; 19: 132–134.

    Article  CAS  Google Scholar 

  12. Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the expert help of JP Le Couedic for BCR-ABL sequencing.

Author information

Authors and Affiliations

  1. INSERM U362, Unite de thérapie cellulaire, Institut Gustave Roussy, Villejuif, France

    S Flamant & A G Turhan

Authors
  1. S Flamant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A G Turhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A G Turhan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flamant, S., Turhan, A. Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection. Leukemia 19, 1265–1267 (2005). https://doi.org/10.1038/sj.leu.2403786

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403786

This article is cited by

Search

Advanced search

Quick links